BioCentury
ARTICLE | Clinical News

Albuvirtide: Interim Phase III data

July 11, 2016 7:00 AM UTC

Interim data from 96 evaluable HIV-infected patients who failed first-line antiretroviral therapy (ART) in the modified intent-to-treat (mITT) population of the open-label, Chinese Phase III TALENT tr...